Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of TERN-701 in Chronic Myeloid Leukemia
2023-507677-18-00Phase 2Authorised
- Sponsor
- Terns Pharmaceuticals
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, single-arm trial of TERN-701 in chronic myelogenous leukemia (CML), sponsored by Terns Pharmaceuticals. Primary endpoints: Safety and tolerability of TERN-701, Pharmacokinetics of TERN-701 and 1 more. Planned start May 2024; status: authorised.
02
Drugs
TERN-701
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2023-507677-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507677-18-00.